Mestastop Solutions
Date of Foundation
2019

Mestastop Solutions

Revolutionizing Cancer Treatment with Mestastop Solutions

The Idea origin story

Mestastop is innovatively tackling cancer by focusing on delaying metastasis, the cause of 90% of cancer deaths. Our approach decouples cell proliferation from metastasis using patient translational data and AI, differing from the traditional anti-proliferative treatments. We're on our way to phase II clinical trials, targeting a revolutionary change in cancer treatment.

The Mission

Vision: To eliminate metastasis from cancer vocabulary, giving patients renewed hope. Mission: To identify novel targets for metastasis, and develop companion diagnostics for accurate study trials.

Clients

Our customers are Biopharma companies engaged in Oncology drug discovery, particularly those seeking to reposition their candidates for larger markets.

Problems we solve

Client’s problem

Our solution tackles the life-threatening problem of metastasis. Current drugs only briefly extend survival—our innovative platforms aim to dramatically increase that by a minimum of 24 months. Utilizing unique targets and repurposed drugs, we're transforming patient outcomes through advancements in anti-metastatic treatments and companion diagnostics.

Confirmation of problem

The problem is serious because 90% of cancer deaths are due to metastasis, and current treatment doesn't inhibit it. Our goal is to delay and prevent metastasis, enhancing patients' lives.

Solution

We've patented three platforms that identify first-in-class targets and 100% metastasis inhibiting molecules. Utilizing patient data, we reveal key steps of metastasis for drug discovery.

Our technologies

This solution is based on technologies

How it works

The patient-derived knowledge of the rate-limiting steps is then further exploited to identify and validate novel targets and molecules for novel discovery, drug repurposing and companion diagnostics.

Value for the client

We increase survival rates by targeting cancer metastasis with innovative treatments and diagnostics, dramatically improving patient outcomes.

Market and strategy

Market size

5000

mln/year

We estimate the market size for which our solution is designed in monetary terms as follows

Market share goal

2

% of the market

Is our goal in the next 3 years

Team

My name’s

Arnab Roy Chowdhury

My key role in the product

My key role as the founder of Mestastop involves spearheading both scientific research and business strategies.

Team size and key members

Our team consists of 17 proven professionals with over 200 years combined experience. We are privileged to have seven PhDs trained from renowned institutions like Harvard and MIT, as well as industry leaders like Amgen and Global CROS. Currently, we remain open to individuals who bring unique skills or innovative insights that can complement our existing strengths while propelling the business forward.

Competitors

Competitors

Mestastop competes with Hibercell, Ona Therapeutics, Volastara, Recursion and Hummingbird Biosciences in the solid tumours realm. However, our unique bedside-to-bench approach gives us an edge. Other competitors may include companies working on AI applications for cancer treatment.

Our Advantages

We've pioneered in identifying novel metastasis targets. Our unique focus is on the secondary microenvironment's role in metastasis, rather than initial dissemination. We've proven our molecules can delay metastasis without affecting tumor growth through animal models and retrospective clinical trials show survival-promoting drugs are indeed metastasis-delaying substances.

Business model

Our revenue comes from B2B outlicensing of our molecules and platforms, involving upfront payments, milestone-based earnings, and royalties.

Traction

Our platform secured US and India patents with regulatory approval for our inaugural Indian clinical trial. We're crafting an Investigational New Drug brochure for a second candidate while propelling our discovery program into the competitive stage.

We've identified a pre-IND candidate, accumulated a year's worth of clinical data on one program, secured FDA IND approval for two candidates, and completed at least one out-licensing deal. Our trajectory speaks to our progress and dedication.

Metrics

Last month, we made headway in our business development endeavors by approaching 17 pharmaceutical companies. While the response was primarily positive with a 70% interest rate, there were also minor setbacks as five either declined or didn't respond to us at all.

As a pre-revenue startup, we've dedicated 7 years and $2M to intensive R&D. Over the next 18-24 months, we foresee an additional investment of $3M towards this cause. Our financial anticipation is set on closing a minimum deal value of $5M within the same timeframe.

Incorporation

Our company incorporated in

Bangalore,

Key risks

The primary risks include competitors developing similar solutions, regulatory hurdles delaying or impeding progression to market, changes in the drug approval landscape, and potential difficulties in sourcing consistent funding.

Investments

$

2000000

We raised investments

Our Investors

angels investors, seed funding firms, friends and family, self

Rising Investments

$

3000000

Currently, we are raising investments

$

15000000

Estimated pre-investment valuation of the company

We’re looking for a co-founders

I’m seeking a dynamic co-founder to join our pioneering startup, Mestastop Solutions. We’re innovatively addressing cancer treatment by focusing on delaying metastasis, the cause of 90% of cancer deaths. Leveraging patient clinical data and AI, we have patented three platforms that identify first-in-class targets and 100% metastasis inhibiting molecules. We offer a unique bedside-to-bench strategy, setting us apart from competitors in the solid tumours realm like Hibercell, Ona Therapeutics, Volastara, Recursion and Hummingbird Biosciences. We have already dedicated 7 years and $2M in intensive R&D securing US and India patents with regulatory approval for our inaugural Indian clinical trial. Our business model involves B2B outlicensing of our molecules and platforms, involving upfront payments, milestone-based earnings, and royalty payments.

Open positions

Article

Read

Additional information

We're trailblazers, pioneering a groundbreaking solution globally to delay clinical metastasis with our unique approach.

Growth